Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world treatment and outcomes of Mantle Cell Lymphoma in Latin America: A multinational cohort analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

LRLuis Felipe RubalcavaBBBrady BeltránJMJosé Luis Álvarez Macías

Discussion

Loading...

Member takes

Overview

Multicenter cohort analysis reveals disparities in treatment access and outcomes for mantle cell lymphoma in Latin America.

Key Points

  • To characterize clinical presentation, treatment approaches, and survival outcomes for patients with mantle cell lymphoma in Latin America.
  • Retrospective cohort study across 19 institutions in 8 LATAM countries.
  • Inclusion of adult patients diagnosed with mantle cell lymphoma with complete data.
  • Analysis of demographics, treatment regimens, and survival outcomes.
  • 222 patients included with median age of 64 years; 72.5% diagnosed at stage III/IV.
  • Overall survival at 36 months was 68.4%; autologous stem cell transplantation improved survival rates.
  • Access to maintenance therapy and targeted agents was notably limited in public institutions.

Cite This Study

Rubalcava et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d9dchttps://doi.org/10.1182/blood-2025-3586
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world outcomes of Mantle Cell Lymphoma in Colombia: A multicenter cohort study2025
  2. 2Contemporary real-world outcomes of mantle cell lymphoma in Colombia: Results from an expanded multicenter cohort.2026
  3. 3Treatment patterns and survival outcomes in patients with Mantle Cell Lymphoma: Interim report of the Asia-Pacific multinational prospective registry study2025 · 1 citations
  4. 4Real-world treatment and safety outcomes of patients with Mantle Cell Lymphoma in the United States2025
  5. 5Survival benefit of autologous transplant (ASCT) for mantle cell lymphoma (MCL) in the California Cancer Registry (CCR).2024 · 1 citations